Hormonal therapy in the management of prostate cancer: From huggins to the present

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 5-15

  Garnick, Marc B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; ESTRAMUSTINE; FLUTAMIDE; KETOCONAZOLE; LEUPRORELIN; MEGESTROL ACETATE;

ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CONFERENCE PAPER; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HOT FLUSH; HUMAN; IMPOTENCE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DIETHYLSTILBESTROL; DRUG THERAPY, COMBINATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 0030939099     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00163-5     Document Type: Conference Paper

References (35)

1. Huggins C, and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
2. Huggins C, Stevens RE Jr, and Hodges CV: Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223, 1941.
3. Huggins C, Scott WW, and Hodges CV: Studies on prostatic cancer. III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 46: 997-1006, 1941.
4. Garnick MB: Prostate cancer: screening, diagnosis and management. Ann Intern Med 118: 804-818, 1993.
5. Garnick MB, and Fair WJ Jr: Prostate cancer: emerging concepts. Ann Intern Med 125: 118-125, 1996.
6. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Pogata GK, Keer HN, and Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398, 1995.
7. Byar DP, and Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 7: 165-170, 1988.
8. Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011-1017, 1967.
9. Garnick MB, and Glode LM, for the Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281-1286, 1984.
10. Blithe B, McRae CU, Espiner EA, Nicholls MG, Conaglen JV, and Gilchrist N: Effect of stilbestrol on sodium balance, cardiac state and renin-angiotensin-aldosterone activity in prostatic carcinoma. BMJ 291: 1461-1464, 1985.
11. deVoogt HJ, Smith PH, Pavone-Macaluso M, dePauw M, Suciu S, and Members of the European Organization for Research on Treatment of Cancer Urological Group: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone actetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135: 303-307, 1986.
12. Pavone-Macaluso M, deVoogt HJ, Viggiano G, Barasolo E, Lardennois B, dePauw M, and Sylvester R: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136: 624-631, 1986.
13. Cox RL, and Crawford ED: Estrogens in the treatment of prostate cancer. J Urol 154: 1991-1998, 1995.
14. Kerle D, Williams G, Ware H, and Bloom SH: Failure of long-term luteinizing-hormone treatment for prostatic cancer to suppress serum luteinizing hormone and testosterone. Br Med J 289: 468-469, 1984.
15. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, and Dorr FA: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
16. Denis LJ, Whetan JL,Carneiro de Moura JL, and Bono A, et al: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119, 1993.
17. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-753, 1995.
18. Kahn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R, Bertagna C, and Edelstein R: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). N Engl J Med 321: 413-418, 1989.
19. Oesterling JE, Epstein JI, and Walsh PC: The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypituitarism. J Urol 136: 1030-1034, 1986.
20. Loughlin K: Should androgen ablation for metastatic PCa be total? Contemp Urol 6: 39-55, 1994.
21. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3238 deaths in 5710 patients. Lancet 346: 265-269, 1995.
22. Waxman J, Labrie F, Crawford D, and Quartey P: Anti-androgens in treatment of prostate cancer (letter). Lancet 346: 1030-1031, 1995.
23. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, and Lemay M, et al: Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44: 29-37, 1994.
24. Fair WR, Aprikian AG, Cohen D, Sogani P, and Reuter V: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16: 516-522, 1993.
25. Fair WR, Wang Y, Cohen D, Cookson M, Russo P, and Dalbagni G, et al: Neoadjuvant androgen deprivation therapy (ADT) in patients with clinically localized prostate cancer-effect on (+) margins and post-operative PSA (abst). J Urol 153: 313A, 1995.
26. Pilepich MV, Krall JM, and Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616-623, 1995.
27. Gleave ME, Goldenberg L, Jones EC, Bruchovsky N, and Sullivan LD: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155: 213-219, 1996.
28. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood D, and Puras-Baez A, for the Lupron Depot Neoadjuvant Prostate Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bN x MO) prostate cancer. J Urol 154: 424-428, 1995.
29. Aprikian AG, Fair WR, Reuter VE, Sogani P, Herr H, Russo P, and Sheinfeld J: Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 74: 630-636, 1994.
30. Cookson M, Fair WR, Wang Y, Aprikian AG, Cohen D, and Soloway SM, et al: Neoadjuvant androgen deprivation and radical prostatectomy in clinically localized prostate cancer (abst). 74th Annual Meeting of the South Central Section of the American Urological Association, Kansas City, MO, September 8-12, 1995.
31. Thompson IM, Renfer LG, Schow DA, and Rozanski RA: pT2 disease following neoadjuvant hormonal therapy is not an artifact as manifested by PSA failure rate (abst). 74th Annual meeting of the South Central Section of the American Urological Association, Kansas City, MO, September 8-12, 1995.
32. Sullivan L, Gleave M, Goldenberg L, Bruchovsky N, and Jones EC: Long-term neoadjuvant hormonal therapy prior to radical prostatectomy in localized prostate cancer. J Urol 151: 435A, 1994.
33. Forman JD, Kumar R, Haas G, Montie J, Porter AT, and Mesina CF: Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. Cancer Invest 13: 8-15, 1995.
34. Roach M: Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Semin Urol 14: 32-38, 1996.
35. Watson RB, and Soloway MS: Neoadjuvant hormonal treatment before radical prostatectomy. Semin Urol 14: 48-56, 1996.